Seven Bridges Blog Advancing Alzheimer’s Treatment and Inclusive Research

This month represented an important step forward in the treatment of Alzheimer’s disease with Eli Lilly announcing the successful results of their phase III clinical trials for their monocolonal antibody (mAB) donanemab. In addition to decreasing the overall amyloid burden, patients on the drug showed slowed disease progression and sustained ... The post Advancing Alzheimer’s Treatment and Inclusive Research appeared first on Seven Bridges.